In particular, APL patients harboring exceedingly uncommon RARα::HNRNPC and RARα::THRAP3 fusions have been documented to achieve CR through the administration of venetoclax and hypomethylating agents such as azacytidine or decitabine (58, 59). Here, RARA is linked to acute promyelocytic leukemia.